Status:
ACTIVE_NOT_RECRUITING
18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
Glioma, Malignant
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Amino acid PET imaging for brain gliomas is gaining acceptance for the diagnosis and monitoring of disease. This is commonly performed in Europe. There is an opportunity to develop this tracer for use...
Eligibility Criteria
Inclusion
- \>= 18 years of age
- High grade brain glioma (Grade 3 and 4)
- No prior radiation or systemic treatment for high grade glioma
- Planned to undergo radiation therapy with the following regimens:
- Grade 3: 54-60 Gy over 30 fractions with temozolomide
- Grade 3: 40Gy over 15 fractions with temozolomide
- Grade 4: 60 Gy over 30 fractions, with or without temozolomide o Grade 4: 40 Gy over 15 fractions, with or without temozolomide
- Able to tolerate PET/MRI scan with intravenous contrast
- Willing to provide informed consent.
Exclusion
- MRI contraindication
- Creatinine clearance \< 30mL/min
- Inability to lie still for 40 minutes
- Gadolinium allergy
- Prior PET imaging
- Positive pregnancy test
- Breastfeeding
- Patient unable to follow the protocol for any reason
Key Trial Info
Start Date :
December 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06499831
Start Date
December 15 2021
End Date
January 31 2026
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N2M5